Envveno Med Stock Price, News & Analysis

ENVVENO MEDICAL CP WT 26 (trading under the symbol NVNBW) is associated with enVVeno Medical Corporation, a company that files reports with the U.S. Securities and Exchange Commission under that name. According to SEC filings, enVVeno Medical Corporation maintains its principal executive offices in Irvine, California and communicates regularly with stockholders through annual meetings, proxy materials, and current reports on Form 8-K.

The available regulatory filings show that the company’s common stock is listed on the Nasdaq Capital Market. In an 8-K dated October 10, 2025, enVVeno Medical Corporation reported receiving a notice from The Nasdaq Stock Market LLC indicating that the closing bid price of its common stock had fallen below the minimum bid price requirement of $1.00 per share for 30 consecutive business days under Nasdaq Listing Rule 5550(a)(2). The filing explains that this notice did not have an immediate effect on the listing of the company’s common stock and outlines the time periods and conditions for regaining compliance, including the potential use of a reverse stock split if needed.

Corporate governance and stockholder interaction are recurring themes in the company’s disclosures. A Definitive Proxy Statement on Schedule 14A dated October 30, 2025 describes the 2025 Annual Meeting of Stockholders, held via live webcast, and details several proposals submitted to stockholders. These include the election of Class II directors, an advisory vote on the compensation of named executive officers, ratification of the company’s independent registered public accounting firm, and consideration of a 2025 Equity Incentive Plan. The proxy statement also notes that the company’s annual report on Form 10-K/A for the year ended December 31, 2024 is available through the SEC’s website.

Subsequent Form 8-K filings dated December 12, 2025 report the voting results from the 2025 Annual Meeting. Stockholders elected two Class II directors to three-year terms, approved on a non-binding basis the compensation of the company’s named executive officers, and ratified the appointment of CBIZ CPAs P.C. as the company’s registered public accounting firm for the fiscal year ending December 31, 2025. Stockholders did not approve the proposed 2025 Equity Incentive Plan, and the filings state that the company’s 2016 Omnibus Incentive Plan therefore remains in effect. Stockholders also granted the Board of Directors authority to effect a reverse stock split of the company’s common stock at a ratio between one-for-five and one-for-thirty-five, with the exact ratio and timing left to the board’s discretion.

enVVeno Medical Corporation’s filings also describe capital markets activity. In an 8-K dated October 30, 2025, the company reported entering into an At-the-Market Offering Agreement with Ladenburg Thalmann & Co. Inc. This agreement allows the company to sell shares of its common stock from time to time through the agent in transactions characterized as at-the-market equity offerings under Rule 415 of the Securities Act of 1933. The filing explains that sales, if any, may occur through ordinary brokers’ transactions on the Nasdaq Capital Market at prevailing market prices or as otherwise agreed with the agent, and that the company is not obligated to sell any shares under the program.

Regulatory interaction is another important aspect of the company’s profile. An 8-K dated November 13, 2025 reports that enVVeno Medical Corporation issued a press release announcing it had received an unfavorable appeal decision from the U.S. Food & Drug Administration in response to its Premarket Approval application for VenoValve®, described in the filing as a surgical replacement venous valve for treating severe deep chronic venous insufficiency. The company notes that the press release is furnished as an exhibit to that report. The Definitive Proxy Statement further discusses an appeal process with the FDA related to a not-approvable decision to market and sell VenoValve in the United States, and indicates that the outcome of this appeal has implications for enVVe, described as a next generation transcatheter replacement venous valve.

Corporate governance documentation in the proxy statement covers topics such as board composition, director independence, board committees, code of conduct, risk oversight, executive compensation, employment agreements, and director compensation. The proxy materials also outline procedures for stockholder communications, future stockholder proposals, and the conduct of virtual stockholder meetings. An 8-K dated November 20, 2025 describes an amendment to the company’s Amended and Restated Bylaws, revising the quorum requirement for meetings of stockholders so that the presence in person or by proxy of holders of thirty-three and one-third percent in voting power of the outstanding shares entitled to vote at the meeting constitutes a quorum, except where otherwise required by law, the certificate of incorporation, or the bylaws.

Because the instrument identified as ENVVENO MEDICAL CP WT 26 (NVNBW) is tied to enVVeno Medical Corporation, investors researching this symbol often review the company’s broader SEC filings for context on governance, capital structure, listing status, and regulatory developments. The filings collectively provide insight into stockholder rights, board authority to undertake actions such as reverse stock splits, and the company’s interactions with both capital markets and regulatory agencies.

Key aspects highlighted in SEC filings

• Listing and compliance: Notice from Nasdaq regarding the minimum bid price requirement for the company’s common stock and the associated compliance periods.
• Stockholder governance: Annual Meeting of Stockholders conducted via live webcast, with proposals on director elections, executive compensation, auditor ratification, and equity incentive plans.
• Capital raising framework: At-the-market equity offering program established through an agreement with a sales agent, allowing potential issuance of common stock under an effective shelf registration statement and prospectus supplement.
• Corporate bylaws: Amendment to quorum requirements for stockholder meetings, setting a threshold based on a percentage of voting power of outstanding shares.
• Regulatory matters: FDA-related appeal process concerning the VenoValve Premarket Approval application and references to the enVVe next generation transcatheter replacement venous valve.

FAQs about ENVVENO MEDICAL CP WT 26 (NVNBW)

• What company is associated with the NVNBW symbol?
  According to SEC filings, NVNBW is associated with enVVeno Medical Corporation, which files reports under that corporate name and holds its principal executive offices in Irvine, California.
• On which market is the related common stock listed?
  An 8-K dated October 30, 2025 states that sales under the company’s at-the-market equity program may include transactions on the Nasdaq Capital Market, indicating that the company’s common stock is listed there.
• What did Nasdaq’s October 2025 notice to the company involve?
  In an 8-K dated October 10, 2025, enVVeno Medical Corporation reported receiving a notice from Nasdaq that the closing bid price of its common stock had been below $1.00 per share for 30 consecutive business days, meaning the company no longer met the minimum bid price requirement for continued listing. The notice did not immediately affect the listing and outlined time periods for regaining compliance.
• What authority did stockholders grant regarding a reverse stock split?
  Form 8-K filings dated December 12, 2025 report that stockholders approved a proposal granting the Board of Directors authority to effect a reverse stock split of the company’s common stock at a ratio between one-for-five and one-for-thirty-five, with the exact ratio and timing to be determined by the board, if implemented.
• Was a new equity incentive plan approved at the 2025 Annual Meeting?
  The same December 12, 2025 8-K filings state that stockholders voted against the adoption of the enVVeno Medical Corporation 2025 Equity Incentive Plan, and as a result, the company’s 2016 Omnibus Incentive Plan remains in effect.
• What capital raising mechanism did the company establish in October 2025?
  An 8-K dated October 30, 2025 describes an At-the-Market Offering Agreement with Ladenburg Thalmann & Co. Inc., under which the company may sell shares of its common stock from time to time in at-the-market equity offerings pursuant to an effective shelf registration statement and related prospectus supplement.
• How did the company describe its interaction with the FDA regarding VenoValve?
  An 8-K dated November 13, 2025 reports that the company issued a press release announcing an unfavorable appeal decision from the FDA on its Premarket Approval application for VenoValve, described as a surgical replacement venous valve for treating severe deep chronic venous insufficiency. The Definitive Proxy Statement further discusses an appeal process and its implications for both VenoValve and enVVe.
• What change was made to the company’s bylaws in November 2025?
  In an 8-K dated November 20, 2025, the company reports that its Board of Directors approved an amendment to the Amended and Restated Bylaws revising Section 1.5, so that a quorum for stockholder meetings generally consists of holders of thirty-three and one-third percent in voting power of the outstanding shares entitled to vote, present in person or by proxy, unless otherwise required.